Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: Implications for the development of generic versions of low-molecular-weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 74-85

  Jeske, Walter P ^a   Walenga, Jeanine M ^a   Hoppensteadt, Debra A ^a   Vandenberg, Curtis ^a   Brubaker, Aleah ^a   Adiguzel, Cafer ^a   Bakhos, Mamdouh ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Generic; Low molecular weight heparin; Pharmacodynamic

Indexed keywords

ARDEPARIN; CERTOPARIN; CLENOX; CUTENOX; DALTEPARIN; DILUTOL; DRIPANINA; ENOXAPARIN; GENERIC DRUG; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPENOX; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; BIOEQUIVALENCE; COMMERCIAL PHENOMENA; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DEPOLYMERIZATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG NOMENCLATURE; DRUG POTENCY; DRUG STRUCTURE; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

BIOLOGICAL AVAILABILITY; DRUG APPROVAL; DRUGS, GENERIC; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR WEIGHT; PROTHROMBIN; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 43149106965     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066026     Document Type: Review

References (35)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;126:188S-203S
2. Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost 2001;27: 503-511
3. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193:395-400
4. Khorana AA, Sahni A, Aldand OD, et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23:2110-2115
5. Bray B, Lane DA, Freyssinet JM, et al. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J 1989;262:225-232
6. Jeske WP, Walenga JM, Fareed J. Differentiating between the low molecular-weight heparins used for venous thromboembolism treatment and prophylaxis. Thrombosis Clin 2008; in press
7. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999;25(Suppl 3): 17-25
8. Walenga JM, Petitou M, Samama M, et al. Importance of a 3-O-sulfate in a heparin pentasaccharide for antithrombotic activity. Thromb Res 1988;52:553-563
9. Becker RC. New thrombolytic, anticoagulants and platelet antagonists: the future of clinical practice. J Thromb Thrombolysis 1999;7:195-220
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601
11. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447-452
12. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004;30:703-713
13. Leong W, Hoppensteadt DA. Generic forms of low molecular weight heparins: some practical considerations. Clin Appl Thromb Hemost 2003;9:293-297
14. U.S. Food and Drug Administration. 2003P-0064: Withhold approval of generic Lovenox (enoxaparin sodium injection). Available at: http://www.fda.gov/ohrms/dockets/DOCKETS/03p0064/03p0064.htm. Accessed December 20, 2007
15. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999;25(Suppl. 3):5-16
16. Enoxaparin sodium. Pharmacopeiac Forum 2007;33:52-57
17. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(Suppl 1): 31-38
18. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers. Thromb Haemost 1995;73:630-640
19. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low-molecualr weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401
20. Criteria and evidence to assess actual or potential bioequivalence problems. Volume 21 CFR 320. 33: Federal Register; 1998
21. Linhardt RJ, Capila I. Heparin-protein interactions. Angew Chem Int 2002;41:390-412
22. Lindahl U, Backstrom G, Thunberg L, et al. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A 1980;77:6551-6555
23. Petitou M, Lormeau JC, Choay J. Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem 1988;176:637-640
24. Nugent MA. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci U S A 2000;97:10301-10303
25. Ahsan A, Jeske W, Hoppensteadt D, et al. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci 1995;84:724-727
26. Ahsan A, Jeske W, Mardiguian J, et al. Feasability study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins. J Pharm Sci 1994;83:197-201
27. Linhardt RJ, Galliher PM, Cooney CL. Polysaccharide lyases. Appl Biochem Biotechnol 1986;12:135-176
28. Jeske WP, Neville B, Ma Q, et al. Effect of 1,6-anhdro bicyclic ring structure on the pharmacokinetic and pharmacodynamic behavior of low molecular weight heparin. Blood 2004;104:abstract 1868
29. Jeske W, Fareed J. Antithrombin III and heparin cofactor II mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. Semin Thromb Hemost 1993; 19(suppl 1):241-247
30. Ahmad S, Jeske WP, Ma Q, et al. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thromb Res 2001; 102:143-151
31. Hoppensteadt DA, Jeske WP, Walenga JM, et al. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Thromb Res 1999;96:115-124
32. Heparin sodium. United States Pharmacopeia. 29th Revision. Rockville, MD: The US Pharmacopeial Convention; 2006
33. Jeske WP, Walenga JM, Ackerman PD, et al. Assay dependent variations in the anticoagulant and protamine sulfate neutralization profiles of generic copies of enoxaparin. Blood 2006;108:272a
34. Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007;357:1993-1996
35. Fareed J, Walenga JM, Hoppensteadt DA, et al. Immunogenic potential of generic versions of LMWHSs may not be the same as the branded products. Available at: www. natfonline.org/november_2007/etrhombosis_nov2007.html. Accessed December 23, 2007